In an effort to reduce the cost of breast cancer screening several studies have explored the possibility ofusing risk factors to select a high-risk group ofwomen and then restrict screening to that group. The results of these studies have been almost entirely negative and so it is not possible at present to classify any woman as at such low risk that she need not be screened. Nevertheless it is well known that some groups of women can be identified as being at higher risk than the general population. In this study it is assumed that each woman will be offered one screen at which risk factor information will be collected. The usual screening policy is then one ofuniform intervention in which the interval to the next screen is the same for all women: the interval that is currently recommended in the UK is three years. An alternative is a risk strategy in which the time to the next screen depends on the woman's risk status; thus the total number of screens available to the population are distributed according to risk status. Using data from the Edinburgh randomised trial of breast cancer screening these policies have been compared. It is estimated that the proportion of cases detected by screening in the three years following the completion of the initial screening round could be raised from 60% to 67% by adopting a risk strategy. Lead time benefits are also quantified as are the comparisons for an established screening programme.
In the Edinburgh randomised trial of breast cancer screening,' half ofthe geographical female population aged 45-64 has been randomly selected for an invitation to screening by 2-view mammography and clinical examination. Thereafter repeat invitations are issued annually to those women who accept the initial invitation; screening is by annual clinical examination and biannual single oblique view mammography given two, four, and six years after the initial screen. Five years of follow-up have been completed. After seven years of follow-up breast cancer mortality in the population who were offered screening will be compared with that in the control population.
Randomised trials in other countries2 3 have already demonstrated a significant reduction in breast cancer mortality in a population invited to screening. The Forrest report4 has recommended population screening in the UK for women aged 50-64 by mammography and at three yearly intervals.
The current trials in the UK1 5 are expected to report the results of their mortality comparisons in 1988/89. These will describe the effect of offering annual clinical examination and biannual mammography to British women. Such frequent screening is a major commitment of public resources. Yet it is not certain that an alternative programme with less frequent screening will have a similar impact on mortality. The issues of cost-effectiveness are complex; after considering relevant information the Forrest report recommended the interval of three years between screens. This would be the same for all women of the appropriate age. Since, however, not all women have the same risk of disease it is possible that a policy of allocating women to schedules with different intervals between screens would be preferable. This study examines this possibility.
Methods
The first step was to derive a discriminant function using the 14 089 women who were cleared of breast cancer at their first screen in the Edinburgh breast 193 Freda E Alexander, M Maureen Roberts, Anne Huggins, and Berenice B Muir screening programme. In the subsequent five years, 137 of these women were diagnosed as having breast cancer; these were the "cases", and the remaining 13 952 are the "controls". This is the "initial cohort" of the trial. We are confident that the data on subsequent incidence are virtually complete since the women are followed up by two methods: by reference to the pathology registers of Edinburgh hospitals and by flagging at the Scottish General Registry Office. Altogether 100 of the cases were detected at later screening rounds, but all cases arising in the initially "healthy" population were included in the analysis. The data were prepared for analysis using Fortran 77 programs and the discriminant function was derived by logistic analysis with the statistical package GLIM.
The second step was to use the discriminant function to predict subsequent risk. Its ability to predict would be overfavourably assessed if the existing data were used for this purpose; this is the statistical problem of "shrinkage". So the discriminant function coefficients were preshrunk using the method of Copas (equation 8-5 in ref. 7) . Each regression coefficient was multiplied by 0 9 and then the constant term was adjusted to ensure that the mean predicted risk of future disease was correct. This yields a function which is an approximately unbiased predictor of future risk.
As the sample of 14 089 was large we were able to assume that it accurately represented the distribution of the risk factors in any similar future population. The application of the predictor to this population provided estimates of future disease.
The third step was to split the population into three groups: lower, medium, and higher risk groups (the lower and higher risk groups being of equal size). Using a model8 which has been derived by modifying that of Day and Walter,9 we were able to estimate the proportions of cases detected and the average amount by which their diagnosis was advanced in two alternative hypothetical screening programmes: (a) screening by mammography at three-yearly intervals for all women, and (b) screening by mammography at 18-monthly intervals for the high-risk group, at three-yearly intervals for the medium-risk group, and at six-yearly intervals for the low-risk group. These were evaluated and compared over the first three years after the start of screening, over the first six years, and in a long-established screening programme.
The details of applying the model to the present situation and the assumptions involved are given in the appendix.
Results
The proportions of cases and controls in each age group and with each risk factor are shown in tables 2 and 3. Crude odds ratios are given in table 3. All are Note: These correspond to the observed rate of 137/14000 women-years and are higher than would be expected in either an unscreened population or a population with an established screening programme. Corresponding rates for these are 3-52, 1 64, and 0-87 but deriving these requires assumptions that are described in the appendix.
was calculated by adding together the appropriate coefficients; this was the natural logarithm of her predicted future risk of disease. Figure 1 shows the cumulative proportions of cases and of the general population plotted against score. The curves diverge in the central region, showing pictorially the amount of discrimination that is obtained. Examination of fig 1 suggests that appropriate sizes for high-and low-risk subgroups ofthe population are 20%. The predicted risks were averaged over each of these and over the medium-risk group, and the results are shown in table 5. These were taken as underlying incidence rates and applied to the mathematical model developed in ref. cases, but the rate of disease in this group is 0-8/1000 women-years, which is far from negligible. These women certainly require some repeat screening. We have used theoretical methods to quantify the benefits that could be derived from a risk strategy using risk information available at present. The use of the risk strategy would increase the proportion ofcases detected by screening in the few years after the start ofa screening programme from approximately 60% to approximately 67%. The order of magnitude represents a useful improvement, but to put it in context it should be remembered that the corresponding estimate for the present programme is 78%.
Three conclusions are suggested by this study. Firstly, risk factor information should be collected in some new programme with a three-yearly interval so as to permit prospective evaluation. Secondly, some research should be directed to factors that will positively identify a truly low-risk population of reasonable size.'4 Thirdly, the "high-risk" group should be identified and monitored in future screening programmes to seee whether, for them, the three-yearly interval between screens is indeed too long.
Few assumptions have been made in the earlier part of this study except that we disregard any age effect. We did this because at present no definite age relationship is evident in Edinburgh, but more work is certainly necessary to clarify this. Several assumptions have been made in the modelling process which led to estimates of the proportion of cases detected and of lead time. Three of these merit discussion here.
Firstly, we have assumed that the risk status ofeach individual woman remained unchanged from the time of her first screen. In practice, it would certainly change: for example, her menstrual status would change, and the information collected at screening would be replaced with new information once she had been screened again. Thus after each screen a woman could be re-allocated to a different risk-category. This would be done automatically by computer.
Secondly, we have taken observed risk of breast cancer diagnosis over a five-year period following a negative screen and used this to estimate underlying incidence rates for subgroups of the population. This assumes that the parameters of the screening programme (false negative rate and mean sojourn time) are independent of the risk factors; this might not be true since, for example, some of the factors could possibly influence tumour growth rate and hence sojourn time. A simulation study'5 has used the same predictor but with otherwise different assumptions and confirmed these results over the first few years of a screening programme.
Thirdly, we are of course assuming a future programme in which the performance of screening is similar to that in the present Edinburgh programme. It may well be that both technology and skills will improve in future.
Whenever a mathematical formula is used to allocate public resources there. is concern about "fairness". It has been shown theoretically'6 17 that the allocation which minimises the overall risk of the undesirable event at the same time ensures that each member of the population then has the same chance of experiencing it irrespective of their initial risk status; thus the proposed strategies are "fair" in the sense that they equalise the probabilities ofa symptomatic breast cancer diagnosis.
A more fundamental objection lies in our choice of end-point which was detection by screening; ideally we should optimise years of life saved. The aggression displayed by breast tumours covers a wide spectrum, and screening is probably of little benefit to those at either end of the spectrum. Our results extend to benefits for years of life only if this spectrum of aggression is similar in each of the three risk groups. We have, however, searched the literature and can find no definite evidence linking the risk factors with prognosis or with tumour growth rate. We hope that future research will examine this question.
We must finally emphasise that it is unknown whether a policy of allocating different recall times in logit p = a + BT x where x is a vector denoting risk factor values and p is the probability of being diseased.
The preshrunk predictor is then logit p = a + BT XO + kBT (x -x,) where k is the shrinkage, x. is the vector of mean values, and p now denotes the probability of future disease. More precisely: since the initial data were for five years' follow-up from the first screen, p is the probability of disease within the next five years. These divided by 5 yield average annual predicted incidence rates over the next five years and are given for each risk category in table 5.
The screening model in ref. 8 requires knowledge of the underlying incidence rate, J, in the population. Then in a population in regular screening the incidence rates over five years are SJ where S is a function of the screening parameters. If the screening parameters are the same for the three risk groups, it follows that the underlying incidence rates are in the same ratio as the five-year rates. Hence the underlying rates can be obtained from those in table 5 by multiplying by a constant b, to give underlying rates JH, JM, JL in the three risk groups satisfying Use of risk factors to allocate schedules for breast cancer screening where J = 1-86 is the underlying rate in the whole population.
It must be emphasised that this involves the assumption that the screening parameters are independent of the risk factors.
Estimating the performance of screening
For a population with underlying incidence rates J/c x 1000 women-years and screened by mammography every 2c years with false negative rate B and mean sojourn time m x c years the rates of screen detected and symptomatic cancers over three complete time periods of 2c years are given by the model described in ref. 8 .
To estimate the performance of screening when mammography is given every three years we take c = 1S5, m = 4-98/1S5 and J = 186 x 1-5.
To estimate the performance of the risk strategy the three risk groups were considered separately. 
